Stoke Therapeutics, Inc.

NasdaqGS:STOK 株式レポート

時価総額:US$599.1m

Stoke Therapeutics 過去の業績

過去 基準チェック /06

Stoke Therapeuticsの収益は年間平均-22.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.1% 63.1%割合で 増加しています。

主要情報

-22.2%

収益成長率

-7.2%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率63.1%
株主資本利益率-45.4%
ネット・マージン-629.9%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 07

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 14

It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

May 30
It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Apr 04

Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

Mar 21
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Dec 07
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

May 09
Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

May 06
Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

May 02
Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Dec 13
We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M

Aug 08

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS misses by $0.02

May 10

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

収支内訳

Stoke Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:STOK 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 2417-1054787
30 Jun 2415-1044486
31 Mar 248-1094185
31 Dec 239-1054182
30 Sep 239-1034082
30 Jun 239-1054081
31 Mar 2315-994079
31 Dec 2212-1013978
30 Sep 229-1003873
30 Jun 226-963767
31 Mar 223-943463
31 Dec 210-863254
30 Sep 210-762947
30 Jun 210-672641
31 Mar 210-582335
31 Dec 200-522132
30 Sep 200-481930
30 Jun 200-431729
31 Mar 200-381427
31 Dec 190-321224
30 Sep 190-26920
30 Jun 190-21715
31 Mar 190-16611
31 Dec 180-1348

質の高い収益: STOKは現在利益が出ていません。

利益率の向上: STOKは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: STOKは利益が出ておらず、過去 5 年間で損失は年間22.2%の割合で増加しています。

成長の加速: STOKの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: STOKは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: STOKは現在利益が出ていないため、自己資本利益率 ( -45.43% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘